<DOC>
	<DOCNO>NCT00883116</DOCNO>
	<brief_summary>The primary purpose study investigate whether administration ixabepilone result superior outcome assess overall survival compare achieved standard chemotherapy ( paclitaxel doxorubicin ) woman advance endometrial cancer progress follow first-line chemotherapy .</brief_summary>
	<brief_title>A Study Ixabepilone Second-line Therapy Locally Advanced , Recurrent , Metastatic Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Key Inclusion Criteria Women age 18 year old Histologic cytologic diagnosis endometrial carcinoma Evidence cancer advance , recurrent , metastatic curable local measure , surgery radiation . Karnofsky performance status &gt; =70 Measurable nonmeasurable disease progress since last treatment . If disease confine solitary lesion , neoplastic nature must confirm histology cytology . Disease previously irradiate field acceptable site measurable disease clear progression since completion radiotherapy . All therapy direct endometrial cancer must discontinue 21 day prior start treatment , except hormonal therapy must discontinue least 1 week prior start study treatment . Concurrent administration hormone replacement therapy allow . Prior therapy : Participants must fail 1 prior platinumbased chemotherapeutic regimen endometrial cancer . May receive 2 prior chemotherapy regimens 1 regimen give stage I II disease . May receive number prior noncytotoxic regimen monoclonal antibody , cytokine , signal transduction inhibitor , hormonal therapy . Previous radiation therapy allow . Key Exclusion Criteria Carcinosarcoma ( malignant mixed mullerian tumor ) Endometrial leiomyosarcoma endometrial stromal sarcoma Participants receive prior chemotherapy endometrial cancer ≥2 prior chemotherapy regimen ( exception define protocol ) Known brain metastasis Receipt prior ixabepilone therapy Concurrent active infection require antibiotic therapy Concurrent unstable disease debilitate illness , congestive heart failure , unstable angina , myocardial infarction , cardiac disease could jeopardize participation , within last 6 month For participant whose prior therapy include anthracycline therefore may randomize doxorubicin , leave ventricular ejection fraction &lt; 50 % measure multigated radionuclide angiography echocardiography History malignancy , except nonmelanoma skin cancer , carcinoma situ cervix , carcinoma situ breast , within last 5 year treat chemotherapy Known human immunodeficiency viral infection Psychiatric disorder condition render participant incapable comply protocol requirement Absolute neutrophil count &lt; 1500/mm^3 Platelets &lt; 100,000/mm^3 Hemoglobin &lt; 9 g/dL Total bilirubin &gt; 1.5*upper limit normal ( ULN ) , except Gilbert 's disease Aspartate aminotransferase alanine aminotransferase &gt; 2.5*ULN Serum creatinine &gt; 1.5*ULN Grade ≥2 neuropathy ( sensory motor ) No concurrent therapy ( chemotherapy , hormonal , investigational ) direct endometrial cancer study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>